S'abonner

Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways - 04/01/23

Doi : 10.1016/j.jaci.2022.06.028 
Ioana Agache, MD, PhD a, b, , Mohamed H. Shamji, PhD, FAAAAI c, d, , , Nazanin Zounemat Kermani, PhD c, e, Giulia Vecchi, PhD f, Alberto Favaro, PhD f, Janice A. Layhadi, PhD c, d, Anja Heider, PhD g, Didem Sanver Akbas, PhD c, d, Paulina Filipaviciute, MSc c, d, Lily Y.D. Wu, BSc c, d, Catalina Cojanu, MD, PhD a, b, Alexandru Laculiceanu, MD a, b, Cezmi A. Akdis, MD, PhD g, h, , Ian M. Adcock, PhD c, d,
a Faculty of Medicine, Transylvania University, Brasov, Romania 
b Theramed Healthcare, Brasov, Romania 
c National Heart and Lung Institute, Imperial College London, United Kingdom 
d NIHR Biomedical Research Centre, London, United Kingdom 
e Data Science Institute, Imperial College London, United Kingdom 
f Faculty Science Limited, London, United Kingdom 
g Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland 
h Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland 

Corresponding author: Ioana Agache, MD, PhD, Faculty of Medicine, Transylvania University, 2A, Pictor Ion Andreescu, Brasov 500051, Romania.Faculty of MedicineTransylvania University2APictor Ion AndreescuBrasov500051Romania∗∗Mohamed H. Shamji, PhD, FAAAAI, National Heart and Lung Institute, Sir Alexander Fleming Building, Imperial College London, London SW7 2AZ, UK.National Heart and Lung InstituteSir Alexander Fleming BuildingImperial College LondonLondonSW7 2AZUK

Abstract

Background

Unsupervised clustering of biomarkers derived from noninvasive samples such as nasal fluid is less evaluated as a tool for describing asthma endotypes.

Objective

We sought to evaluate whether protein expression in nasal fluid would identify distinct clusters of patients with asthma with specific lower airway molecular phenotypes.

Methods

Unsupervised clustering of 168 nasal inflammatory and immune proteins and Shapley values was used to stratify 43 patients with severe asthma (endotype of noneosinophilic asthma) using a 2 “modeling blocks” machine learning approach. This algorithm was also applied to nasal brushings transcriptomics from U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes). Feature reduction and functional gene analysis were used to compare proteomic and transcriptomic clusters. Gene set variation analysis provided enrichment scores of the endotype of noneosinophilic asthma protein signature within U-BIOPRED sputum and blood.

Results

The nasal protein machine learning model identified 2 severe asthma endotypes, which were replicated in U-BIOPRED nasal transcriptomics. Cluster 1 patients had significant airway obstruction, small airways disease, air trapping, decreased diffusing capacity, and increased oxidative stress, although only 4 of 18 were current smokers. Shapley identified 20 cluster-defining proteins. Forty-one proteins were significantly higher in cluster 1. Pathways associated with proteomic and transcriptomic clusters were linked to TH1, TH2, neutrophil, Janus kinase-signal transducer and activator of transcription, TLR, and infection activation. Gene set variation analysis of the nasal protein and gene signatures were enriched in subjects with sputum neutrophilic/mixed granulocytic asthma and in subjects with a molecular phenotype found in sputum neutrophil-high subjects.

Conclusions

Protein or gene analysis may indicate molecular phenotypes within the asthmatic lower airway and provide a simple, noninvasive test for non–type 2 immune response asthma that is currently unavailable.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Severe asthma, T2 asthma, biomarkers, nasal proteomics, machine learning, trascriptome-associated cluster, endotypes

Abbreviations used : AUC, ENDANA, ES, GINA, ML, ROC, T2, TAC, U-BIOPRED


Plan


 This study was funded, in part, by the PN-II-RU-TE-2014-4 programme, the UK Medical Research Council (MRC) (grant nos. MR/T010371/1 and MR/M016579/1), and the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (BRC). I.M.A. is supported by the Engineering and Physical Sciences Research Council (EPSRC; grant nos. EP/T003189/1 and EP/V052462/1), the UK MRC (grant nos. MR/T010371/1 and MR/M016579/1), and the Wellcome Trust (grant no. 208340/Z/17/Z). N.Z.K. is supported by the UK MRC (MR/T010371/1 and MR/M016579/1). The clinical trial performed by Ioana Agache was funded through the PN-II-RU-TE-2014-4-2303 ENDANA project. All aspects of the research performed at Imperial College London were funded by the BRC and Imperial College Trust. Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes was supported by an Innovative Medicines Initiative Joint Undertaking (no. 115010), resources from the European Union’s Seventh Framework Programme (FP7/2007-2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution (www.imi.europa.eu).
 Disclosure of potential conflict of interest: I. Agache reports research grants from the Romanian Ministry of Education and Research (UEFISCDI) and Actelion/Idorsia and lectures fees from AstraZeneca, Novartis, Chiesi, Sanofi, Mylan, and ALK. M. H. Shamji reports research grants from Immune Tolerance Network, Medical Research Council, Allergy Therapeutics, LETI Laboratorios, and Rovolo Biotherapeutics and lecture fees from Allergy Therapeutics and Leti Laboratorios. C. A. Akdis received research grants from Novartis, Astra Zeneca (AZ), GlaxoSmithKline (GSK), Idorsia, Scibase, EU Horizons Cure, and Swiss National Science Foundation and takes advisory roles in Scibase, Regeneron/Sanofi, and Novartis. I. M. Adcock is supported by the EPSRC (EP/T003189/1 and EP/V052462/1), the UK Medical Research Council (MR/T010371/1 and MR/M016579/1), and the Wellcome Trust (208340/Z/17/Z) and reports investigator-led research grants from GSK and lectures fees from AZ, GSK, Kinexis, and Eurodrug. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 151 - N° 1

P. 128-137 - janvier 2023 Retour au numéro
Article précédent Article précédent
  • Exacerbation-prone pediatric asthma is associated with arginine, lysine, and methionine pathway alterations
  • Kirsten A. Cottrill, Susan T. Stephenson, Ahmad F. Mohammad, Susan O. Kim, Nael A. McCarty, Rishikesan Kamaleswaran, Anne M. Fitzpatrick, Joshua D. Chandler
| Article suivant Article suivant
  • Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3
  • Jonathan M. Gaffin, Carter R. Petty, Ronald L. Sorkness, Loren C. Denlinger, Brenda R. Phillips, Ngoc P. Ly, Benjamin Gaston, Kristie Ross, Anne Fitzpatrick, Leonard B. Bacharier, Mark D. DeBoer, W. Gerald Teague, Sally E. Wenzel, Sima Ramratnam, Elliot Israel, David T. Mauger, Wanda Phipatanakul, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.